Bisphosphonates
Key Points
- Bisphosphonates reduce fracture risk in osteoporosis by inhibiting bone resorption.
- Oral bisphosphonates require strict administration timing: take on rising with plain water only, at least 30 minutes before food, beverage, or other medications.
- Clients must remain upright for at least 30 minutes after dosing to reduce upper-GI and esophageal injury risk.
- Some agents (for example oral ibandronate) require at least 60 minutes upright/fasting timing based on formulation guidance.
- Osteonecrosis of the jaw is a rare but serious complication, especially with IV formulations.
- Invasive dental procedures should be avoided during active bisphosphonate therapy because jaw-healing complications can worsen.
- Calcium and vitamin D supplementation is typically required alongside therapy.
- Alendronate is contraindicated in hypocalcemia, esophageal-emptying disorders, aspiration risk, inability to remain upright after dosing, and pregnancy.
Mechanism
Bisphosphonates bind to hydroxyapatite in bone and are internalized by osteoclasts, inhibiting their resorptive activity. Bone mineral density is preserved or increased with long-term use.
Common Agents and Typical Dosing
| Drug | Typical Adult Dosing |
|---|---|
| Alendronate | 10 mg PO daily or 70 mg PO weekly |
| Ibandronate | 150 mg PO monthly or 3 mg IV every 3 months |
| Risedronate | 5 mg PO daily, 35 mg PO weekly, or 150 mg PO monthly |
| Zoledronic acid | 5 mg IV every 12-24 months for osteoporosis pathways |
Key Nursing Considerations
- Verify formulation schedule carefully (daily vs weekly products differ by indication and regimen).
- Oral administration: take on empty stomach after arising with 6-8 oz plain water, remain upright for at least 30 min, and avoid food/drink (except water) during that window.
- For alendronate pathways, avoid orange juice and other nonwater beverages for at least 2 hours after dosing because absorption decreases.
- Monitor for esophageal irritation with oral formulations.
- Dental exam recommended before initiation, especially IV formulations.
- Avoid invasive dental procedures while actively receiving therapy when possible; coordinate dental care timing before initiation.
- Monitor serum calcium and vitamin D levels.
- Avoid alendronate in severe renal impairment (for example creatinine clearance below 35 mL/min) and in clients with delayed esophageal emptying.
- Instruct clients to report severe musculoskeletal pain promptly because therapy discontinuation may be required.
- For glucocorticoid-associated osteoporosis treatment, anticipate baseline and follow-up bone-density monitoring (about 6-12 months).
- Separate oral bisphosphonates from calcium supplements/antacids because coadministration impairs absorption.
- Review concurrent NSAID/aspirin burden because upper-GI irritation risk can rise with combination therapy.
Related Concepts
- common-musculoskeletal-disorders-recognition-and-care-priorities - Osteoporosis prevention and management.